Join to View Full Profile
Elm and Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-8386
Dr. Hamid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Showkat Hamid is an oncology specialist based in Buffalo, NY, with a focus on hematologic oncology. He completed his internal medicine residency at the University at Buffalo. Dr. Hamid has been serving as an assistant professor at Roswell Park Comprehensive Cancer Center since 2018. His expertise includes health technology, medical education, stem cell transplantation, medical oncology, and cellular therapy. He has contributed to several publications, including on topics such as CAR T cell resistance and management of malignant bowel obstruction. He is also engaged in clinical trials focusing on palliative management of inoperable malignant bowel obstruction.
Clinical Expertise
- Medical education, Stem cell transplantation, Medical oncology, Cellular Therapy, Malignant Hematology, Cancer Immunotherapy
Education & Training
University at BuffaloResidency, Internal Medicine, 2010 - 2025
Government Medical College SrinagarClass of 2006
Certifications & Licensure
IA State Medical License 2013 - Present
FL State Medical License 2025 - 2027
NY State Medical License 2015 - 2027
NJ State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Palliative Management of Inoperable Malignant Bowel Obstruction Start of enrollment: 2019 Jun 26
Publications & Presentations
PubMed
- IFNγ-driven skewing towards Th1 over Th17 differentiationunderlies CRSand neutropenia in CAR-T therapy.Payal Goala, Yongliang Zhang, Nolan J Beatty, Allan Pavy, Shannon L McSain
The Journal of Clinical Investigation. 2025-10-30 - CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma.Marco Davila, Sae Bom Lee, Yun Pyo Kang, Justin Boucher, Jay Mandula
Research Square. 2025-03-31 - Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic c...Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim
Blood Cancer Journal. 2025-03-26
Press Mentions
Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma PatientsFebruary 3rd, 2025
Committees
- Chairman, Therapeutics & pharmacy 2014 - 2016
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
